α-Enolase (1-19)-biotin Peptide (Synonyms: Enolase-1 (1-19)-biotin) |
| Catalog No.GC52253 |
A biotinylated α-enolase peptide
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
α-Enolase (1-19)-biotin peptide is a biotinylated form of a 19-amino acid N-terminal peptide fragment of α-enolase, a glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate.1 α-Enolase also functions as a cell surface receptor for plasminogen on pathogens and activated immune cells, as an oxidative stress protein in endothelial cells, and as a chromatin binding partner to facilitate transcription.2,3,4 α-Enolase is an autoantigen in asthma, Hashimoto's encephalopathy, and rheumatoid arthritis, and has been found in the serum of pediatric patients with juvenile idiopathic arthritis.5,6,7,8 's α-Enolase (1-19)-biotin Peptide is intended for use as a negative control in the detection of autoantibodies against citrullinated α-enolase and is the non-citrullinated form of Citrullinated α-Enolase (R8 +R13) (1-19)-biotin Peptide .
1.Zhu, X., Miao, X., Wu, Y., et al.ENO1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) in non-Hodgkin's lymphomasExp. Cell Res.335(2)216-223(2015) 2.Song, Y., Luo, Q., Long, H., et al.Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in gliomaMol. Cancer1365(2014) 3.Subramanian, A., and Miller, D.M.Structural analysis of α-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogeneJ. Biol. Chem.275(8)5958-5965(2000) 4.Hsiao, K.-C., Shih, N.-Y., Fang, H.-L., et al.Surface α-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic targetPLoS One8(7)e69354(2013) 5.Nahm, D.-H., Lee, K.-H., Shin, J.-Y., et al.Identification of α-enolase as an autoantigen associated with severe asthmaJ. Allergy Clin. Immunol.118(2)376-381(2006) 6.Moore, T.L., Gillian, B.E., Crespo-Pagnussat, S., et al.Measurement and evaluation of isotypes of anti-citrullinated fibrinogen and anti-citrullinated α-enolase antibodies in juvenile idiopathic arthritisClin. Exp. Rheumatol.32(5)740-746(2014) 7.Yoneda, M., Fujii, A., Ito, A., et al.High prevalence of serum autoantibodies against the amino terminal of α-enolase in Hashimoto's encephalopathyJ. Neuroimmunol.185(1-2)195-200(2007) 8.Cong, Y., Wang, L., Peng, R., et al.Timosaponin AIII induces antiplatelet and antithrombotic activity via Gq-mediated signaling by the thromboxane A2 receptorSci. Rep.638757(2016)
| Cas No. | SDF | ||
| Synonymes | Enolase-1 (1-19)-biotin | ||
| Formula | M.Wt | 0 | |
| Solubility | Storage | -20°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *